HUTCHMED Strengthens Leadership with New Appointment
Today marks an exciting chapter for HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) as it officially appoints Professor Tan Shao Weng as an Independent Non-executive Director and member of its Technical Committee. This impressive addition brings considerable expertise to the team, effective from October 15.
Meet Professor Tan Shao Weng
With over two decades of experience in oncology, Professor Tan's work primarily revolves around thoracic and head and neck malignancies. He holds notable positions at the National Cancer Centre Singapore as the head of Clinical Trials and Epidemiological Sciences, as well as a senior consultant in Medical Oncology. Additionally, he is a respected professor at Duke-NUS Medical School.
Endorsement from Leadership
Dr. Dan Eldar, Chairman of HUTCHMED, expressed his enthusiasm regarding Professor Tan's appointment. He emphasized that Professor Tan's extensive background in early phase clinical trials and innovative therapies is expected to significantly benefit the company. Dr. Eldar noted how his expertise aligns perfectly with HUTCHMED's focus on cancer drug development.
Professor Tan's Contributions to Oncology
Leading the Experimental Cancer Therapeutics Unit at NCCS, which is one of the largest Phase I clinical trial units in Asia, Professor Tan spearheads numerous trials, showcasing his dedication to advancing cancer treatment. Furthermore, he leads critical research aimed at both understanding drug resistance and developing new cancer therapies and biomarkers.
Acknowledgments and Publications
Professor Tan has received various accolades for his contributions to the field, including prestigious awards from the International Association for the Study of Lung Cancer and the American Society of Clinical Oncology. He has authored over 200 peer-reviewed articles in renowned medical journals, establishing himself as a leader in his field.
Educational Background
His academic achievements include a Bachelor of Science with first-class honors in tumor biology from University College London, along with a Bachelor of Medicine and Surgery from St Bartholomew's. Additionally, he earned a PhD from the National University of Singapore, and he is a Fellow of the Royal College of Physicians.
Company Growth and Future Directions
As HUTCHMED continues to expand its reach in the biopharmaceutical industry, the appointment of Professor Tan comes at a pivotal moment. The company remains committed to developing targeted therapies and immunotherapies, aimed at improving outcomes for cancer patients globally. HUTCHMED's first three medicines have been successfully marketed in China, with international approvals, illustrating its growth trajectory.
Looking Ahead
With Professor Tan's unparalleled background in oncology, HUTCHMED is poised not only to innovate further in the realm of cancer treatment but also to enhance its global presence as a leader in biopharmaceutical solutions. His insights and leadership will help drive the company toward fulfilling its mission of delivering impactful therapies to patients worldwide.
Transparency and Governance
In line with governance standards, Professor Tan has confirmed his independence from any conflicts that may affect his role. The appointment will undergo review as per the company's Articles of Association and regulatory guidelines, ensuring HUTCHMED adheres to high standards of corporate governance.
CONTACTS
For Investor inquiries, please contact HUTCHMED at +852 2121 8200 or via email at ir@hutch-med.com. For Media inquiries, FTI Consulting can be reached at +44 20 3727 1030.
Frequently Asked Questions
Who has been appointed as a new board member of HUTCHMED?
Professor Tan Shao Weng has been appointed as an Independent Non-executive Director.
What is Professor Tan's area of expertise?
He specializes in oncology, particularly thoracic and head/neck malignancies.
What recognition has Professor Tan received?
He has received several prestigious awards, including from the IASLC and ASCO.
What are HUTCHMED's primary focuses?
The company focuses on the discovery and commercialization of targeted therapies and immunotherapies for cancer.
How can I find more information about HUTCHMED?
More information can be found on their official website or through their investor contacts.
